Cascading effects of stressors and inflammatory immune system activation: Implications for major depressive disorder

Journal of Psychiatry and Neuroscience

Volumn 34, Issue 1, 2009, Pages 4-20

  Anisman, Hymie ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NORADRENALIN; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANXIETY; ANXIETY DISORDER; BEHAVIORAL STRESS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEPRESSION; DRUG EFFICACY; GENE EXPRESSION; GENE FUNCTION; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HORMONE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOREACTIVITY; IMMUNOTHERAPY; MAJOR DEPRESSION; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN RELEASE; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; REVIEW; SENSITIZATION; SEROTONIN RELEASE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ANIMAL; BRAIN LEVEL; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; MENTAL STRESS; METABOLISM; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ANIMALS; BRAIN CHEMISTRY; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; HUMANS; IMMUNE SYSTEM; INFLAMMATION; STRESS, PSYCHOLOGICAL;

EID: 60849106515     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (239)

1. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998;105:83-107.
2. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110:135-370.
3. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron 2002;34:13-25.
4. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008;85:1-74.
5. Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1996;1:336-42.
6. Reul JM, Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2002;2:23-33.
7. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59:1116-27.
8. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001;7:541-7.
9. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 1999;461:199-233.
10. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
11. Blalock JE. The immune system as a sensory organ. J Immunol 1984;132:1067-70.
12. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11-38.
13. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999;461:25-45.
14. Hayley S, Borowski T, Merali Z, et al. Central monoamine activity in genetically distinct strains of mice following a psychogenic stressor: effects of predator exposure. Brain Res 2001a;892:293-300.
15. Merali Z, Khan S, Michaud DS, et al. Does amygdaloid corticotropin-releasing hormone (CRH) mediate anxiety-like behaviors? Dissociation of anxiogenic effects and CRH release. Eur J Neurosci 2004;20:229-39.
16. Anisman H, Matheson K. Stress, anhedonia and depression: caveats concerning animal models. Neurosci Biobehav Rev 2005; 29:525-46.
17. Dickerson SS, Kemeny ME. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull 2004;130:355-91.
18. Anisman H, Zacharko RM. Multiple neurochemical and behavioral consequences of stressors. Implications for depression. In: File SE, editor. Psychopharmacology of anxiolytics and antidepressants. New York: Pergamon Press; 2001. p. 57-82.
19. Hayley S, Poulter M, Merali Z, et al. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005;135:659-78.
20. Stanford SC. Central noradrenergic neurones and stress. Pharmacol Ther 1995;68:297-342.
21. Keeney A, Jessop DS, Harbuz MS, et al. Differential effects of acute and chronic social defeat stress on hypothalamic-pituitary-adrenal axis function and hippocampal serotonin release in mice. J Neuroendocrinol 2006;18:330-8.
22. Beitia G, Garmendia L, Azpiroz A, et al. Time-dependent behavioral, neurochemical, and immune consequences of repeated experiences of social defeat stress in male mice and the ameliorative effects of fluoxetine. Brain Behav Immun 2005;19:530-9.
23. Doherty MD, Gratton A. Medial prefrontal cortical D1 receptor modulation of the meso-accumbens dopamine responmse to stress: an electrochemical study in freely-behaving rats. Brain Res 1996;715:86-97.
24. Tidey JW, Miczek KA. Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Res 1996;721:140-9.
25. Briones-Aranda A, Rocha L, Picazo O. Influence of forced swimming stress on 5-HT1A receptors and serotonin levels in mouse brain. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:275-81.
26. Neumaier JF, Petty F, Kramer GL, et al. Learned helplessness increases 5-hydroxytryptamine1B receptor mRNA levels in the rat dorsal raphe nucleus. Biol Psychiatry 1997;41:668-74.
27. Weiss JM, Goodman PA, Losito BG, et al. Behavioral depression produced by an uncontrollable stressor: relationship to norepinephrine, dopamine and serotonin levels in various regions of rat brain. Brain Res Rev 1981;3:167-205.
28. Amat J, Baratta MV, Paul E, et al. Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci 2005;8:365-71.
29. Amat J, Paul E, Zarza C, et al. Previous experience with behavioral control over stress blocks the behavioral and dorsal raphe nucleus activating effects of later uncontrollable stress: role of the ventral medial prefrontal cortex. J Neurosci 2006;26:13264-72.
30. Bland ST, Hargrave D, Pepin JL, et al. Stressor controllability modulates stress-induced dopamine and serotonin efflux and morphine-induced serotonin efflux in the medial prefrontal cortex. Neuropsychopharmacology 2003;28:1589-96.
31. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87:873-904.
32. Gresch PJ, Sved AF, Zigmond MJ, et al. Stress-induced sensitization of dopamine and norepinephrine efflux in medial prefrontal cortex of the rat. J Neurochem 1994;63:575-83.
33. Buwalda B, Kole MH, Veenema AH, et al. Long-term effects of social stress on brain and behavior: a focus on hippocampal functioning. Neurosci Biobehav Rev 2005;29:83-97.
34. Stone EA. Central cyclic-AMP-linked noradrenergic receptors: new findings on properties as related to the actions of stress. Neurosci Biobehav Rev 1987;11:391-8.
35. 1B receptors in the brain. Eur J Pharmacol 1995; 294:531-40.
36. 2A receptor mRNA and protein levels after single and repeated stress in rat brain: role in learned helplessness behavior. Neuropharmacology 2005;48:204-14.
37. Ossowska G, Nowa G, Kata R, et al. Brain monoamine receptors in a chronic unpredictable stress model in rats. J Neural Transm 2001; 108:311-9.
38. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
39. Lightman SL. How does the hypothalamus respond to stress? Semin Neurosci 1994;6:215-9.
40. Makino S, Shibasaki T, Yamauchi N, et al. Psychological stress increased corticotropin-releasing hormone mRNA and content in the central nucleus of the amygdala but not in the hypothalamic paraventricular nucleus in the rat. Brain Res 1999;850:136-43.
41. Merali Z, McIntosh J, Kent P, et al. Aversive as well as appetitive events evoke the release of corticotropin releasing hormone and bombesin-like peptides at the central nucleus of the amygdala. J Neurosci 1998;18:4758-66.
42. Schulkin J. Angst and the amygdala. Dialogues Clin Neurosci 2006;8: 407-16.
43. Schulkin J, Morgan MA, Rosen JB. A neuroendocrine mechanism for sustaining fear. Trends Neurosci 2005;28:629-35.
44. Davis M. The role of the amygdala in fear and anxiety. Annu Rev Neurosci 1992;15:353-75.
45. LeDoux JE. Emotion circuits in the brain. Annu Rev Neurosci 2000; 23:155-84.
46. 1 receptor antagonist. Eur J Pharmacol 1997;323:21-6.
47. Keck ME, Muller MB. Mutagenesis and knockout models: hypothalamic-pituitary-adrenocortical system. Handbook of Exp Pharmacol 2005;169:113-141.
48. 1A receptor challenge. Genes Brain Behav 2002;1:174-7.
49. Iredale PA, Terwilliger R, Widnell KL, et al. Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells. Mol Pharmacol 1996;50:1103-10.
50. Contarino A, Dellu F, Koob GF, et al. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res 1999;835:1-9.
51. Smith GW, Aubry JM, Dellu F, et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998;20:1093-102.
52. Timpl P, Spanagel R, Sillaber I, et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998;19:162-6.
53. 1 receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 2001;13:373-80.
54. Muller MB, Zimmermann S, Sillaber I, et al. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 2003;6:1100-7.
55. Bale TL, Contarino AB, Smith GW, et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000;24:410-4.
56. Bale TL, Vale WW. Increased depression like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses. Neuroscience 2003;23:5295-301.
57. Preil J, Müller MB, Gesing A, et al. Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and 2. Endocrinology 2001;142:4946-55.
58. Kozlovsky N, Matar MA, Kaplan Z, et al. Long-term down-regulation of BDNF mRNA in rat hippocampal CA1 subregion correlates with PTSD-like behavioural stress response. Int J Neuropsychopharmacol 2007;10:741-58.
59. Rasmusson AM, Shi L, Duman R. Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock. Neuropsychopharmacology 2002;27:133-42.
60. Smith MA, Makino S, Kvetnansky R, et al. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15:1768-77.
61. Yee BK, Zhu SW, Mohammed AH, et al. Levels of neurotrophic factors in the hippocampus and amygdala correlate with anxiety-and fear-related behaviour in C57BL6 mice. J Neural Transm 2007; 114:431-44.
62. Altar CA. Neurotrophins and depression. Trends Pharmacol Sci 1999;20:59-61.
63. Shirayama Y, Chen AC, Nakagawa S, et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002;22:3251-61.
64. Castrén E, Voikar V, Rantamäki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007;7:18-21.
65. Rogóz Z, Skuza G, Legutko B. Repeated co-treatment with imipramine and amantadine induces hippocampal brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol 2007;58:219-34.
66. Saarelainen T, Hendolin P, Lucas G, et al. Activation of the TrκB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003;23:349-57.
67. Monteggia LM, Luikart B, Barrot M, et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry 2007;61:187-97.
68. 2A agonist treatment on brain-derived neurotrophic factor expression in female rats. Biol Psychiatry 2003;54:59-69.
69. Dwivedi Y, Rizavi HS, Conley RR, et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60:804-15.
70. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70-5.
71. Piccinni A, Marazziti D, Catena M, et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 2008;105:279-83.
72. Huang TL, Lee CT, Liu YL. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J Psychiatr Res 2008;42:521-5.
73. Rothwell NJ. Cytokines - Killers in the brain? J Physiol 1999;514:3-17.
74. Lucas PC, McAllister-Lucas LM, Nunez G. NF-kappaB signaling in lymphocytes: a new cast of characters. J Cell Sci 2004;117:31-9.
75. Rajora N, Boccoli G, Burns D, et al. alpha-MSH modulates local and circulating tumor necrosis factor-alpha in experimental brain inflammation. J Neurosci 1997;17:2181-6.
76. Rigby WF. Drug insight: Different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol 2007;3:227-33.
77. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
78. Dopp JM, Sarafian TA, Spinella FM, et al. Expression of the p75 TNF receptor is linked to TNF-induced NFkappaB translocation and oxyradical neutralization in glial cells. Neurochem Res 2002;27: 1535-42.
79. Ringheim GE, Conant K. Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). J Neuroimmunol 2004;147:43-9.
80. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007;178:2623-9.
81. Maher FO, Clarke RM, Kelly A, et al. Interaction between interferon gamma and insulin-like growth factor-1 in hippocampus impacts on the ability of rats to sustain long-term potentiation. J Neurochem 2006;96:1560-71.
82. Pokrovskaja K, Panaretakis T, Grandér D. Alternative signaling pathways regulating type I interferon-induced apoptosis. J Interferon Cytokine Res 2005;25:799-810.
83. Banks WA. Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol 1999;5:538-55.
84. Wieczorek M, Swiergiel AH, Pournajafi-Nazarloo H, et al. Physiological and behavioral responses to interleukin-1beta and LPS in vagotomized mice. Physiol Behav 2005;85:500-11.
85. Saija A, Princi P, Lanza M, et al. Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci 1995; 56:775-84.
86. Stamatovic SM, Dimitrijevic OB, Keep RF, et al. Inflammation and brain edema: new insights into the role of chemokines and their receptors. Acta Neurochir Suppl 2006;96:444-50.
87. Esposito P, Gheorghe D, Kandere K, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001;888:117-27.
88. Rivest S. How circulating cytokines trigger the neural circuits that control the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology 2001;26:761-88.
89. Rivest S, Lacroix S, Vallieres L, et al. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 2000;223:22-38.
90. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002;25:154-9.
91. Nadeau S, Rivest S. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience 1999;93:1449-64.
92. Kamm K, Vanderkolk W, Lawrence C, et al. The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J Trauma 2006;60:152-7.
93. Ledeboer A, Binnekade R, Brave JJ, et al. Site-specific modulation of LPS-induced fever and interleukin-1 beta expression in rats by interleukin-10. Am J Physiol Regul Integr Comp Physiol 2002;282: R1762-72.
94. Zhu Y, Saito K, Murakami Y, et al. Early increase in mRNA levels of pro-inflammatory cytokines and their interactions in the mouse hippocampus after transient global ischemia. Neurosci Lett 2006; 393:122-6.
95. Sriram K, Matheson JM, Benkovic SA, et al. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxidty: role of TNF-α. FASEB J 2006;20:670-82.
96. Miyahara S, Komori T, Fujiwara R, et al. Effects of repeated stress on expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat hypothalamus and midbrain. Life Sci 2000;66:PL93-8.
97. Nguyen KT, Deak T, Owens SM, et al. Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci 1998;18: 2739-46.
98. Dunn AJ. Cytokine activation of the HPA axis. Ann N Y Acad Sci 2000;917:608-17.
99. Tilders FJH, Schmidt ED. Cross-sensitization between immune and non-immune stressors. A role in the etiology of depression? Adv Exp Med Biol 1999;461:179-97.
100. Hayley S, Staines WM, Merali Z, et al. Time-dependent sensitization of corticotropin-releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-alpha. Neuroscience 2001;106:137-48.
101. Herman JP, Cullinan WE. Neurocircuitry of stress: central control of hypothalamo-pituitary-adrenocorticaI axis. Trends Neurosci 1997;20:78-84.
102. Day HE, Curran EJ, Watson SJ. Jr, et al. Distinct neurochemical populations in the rat central nucleus of the amygdala and bed nucleus of the stria terminalis: evidence for their selective activation by interleukin-1beta. J Comp Neurol 1999;413:113-28.
103. Hayley S, Brebner K, Lacosta S, et al. Sensitization to the effects of tumor necrosis factor-a; neuroendocrine, central monoamine and behavioral variations. J Neurosci 1999;19:5654-65.
104. Linthorst ACE, Flachskamm C, Muller-Preuss P, et al. Effect of bacterial endotoxin and interleukin-1β on hippocampal serotonergic neurotransmision, behavioral activity, and free corticosterone levels: an in vivo microdialysis study. J Neurosci 1995;15:2920-34.
105. Merali Z, Lacosta S, Anisman H. Effects of interleukin-1β and mild stress on alterations of central monoamines: a regional microdialysis study. Brain Res 1997;761:225-35.
106. Shintani F, Kanba S, Nakaki T, et al. Interleukin-1β augments release of norepinephrine, dopamine and serotonin in the rat anterior hypothalamus. J Neurosci 1993;13:3574-8l.
107. Shintani F, Nakaki T, Kanba S, et al. Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. J Neurosci 1995;15:1961-70.
108. Song C, Merali Z, Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 1999;88:823-36.
109. Zhang J, Terreni L, De Simoni MG, et al. Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. Neurochem Int 2001;38:303-8.
110. Zalcman S, Green-Johnson JM, Murray L, et al. Cytokine-specific central monoamine alterations induced by interleukin (IL)-1, IL-2 and IL-6. Brain Res 1994;643:40-9.
111. Bluthe RM, Pawlowski M, Suarez S, et al. Synergy between tumor necrosis factor alpha and interleukin-1 in the induction of sickness behavior in mice. Psychoneuroendocrinology 1994;19:197-207.
112. Brebrier K, Hayley S, Merali Z, et al. Synergistic effects of interleukin-1, interleukin-6, and TNF-α: neuroendocrine, neurochemical and behavioral changes. Neuropsychopharmacology 2000;22: 566-80.
113. van der Meer MJ, Lebeau A, Duval P, et al. Synergism between IL-1 beta and TNF-alpha on the activity of the pituitary-adrenal axis and on food intake of rats. Am J Physiol 1995;268:E551-7.
114. Zhou D, Shanks N, Riechman SE, et al. Interleukin 6 modulates interleukin-1 and stress-induced activation of the hypothalamicpituitary- adrenal axis in male rats. Neuroendocrinology 1996;63:227-36.
115. Perlstein RS, Mougey EH, Jackson WE, et al. Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormone in vivo. Lymphokine Cytokine Res 1991;10:141-6.
116. Anisman H, Poulter MO, Gandhi R, et al. Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations. j Neuroimmunol 2007;186:45-53.
117. Gandhi R, Hayley S, Gibb J, et al. Influence of poly I:C on sickness behaviors, plasma cytokines, corticosterone and central monoamine activity: moderation by social stressors. Brain Behav Immun 2007; 21:477-89.
118. Gibb J, Hayley S, Gandhi R, et al. Synergistic actions of psychosocial and endotoxin challenges: circulation cytokine, corticosterone and behavioral changes. Brain Behav Immun 2008;22:573-89.
119. Goshen I, Kreisel T, Ben-Menachem-Zidon O, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry. In press.
120. Rage F, Silhol M, Tapia-Arancibia L. IL-1beta regulation of BDNF expression in rat cultured hypothalamic neurons depends on the presence of glial cells. Neurochem Int 2006;49:433-41.
121. Saha RN, Liu X, Pahan K. Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 2006;1:212-22.
122. Schulte-Herbruggen O, Nassenstein C, Lommatzsch M, et al. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol 2005;160:204-9.
123. Churchill L, Taishi P, Wang M, et al. Brain distribution of cytokine mRNA induced by systemic administration of interleukin-1beta or tumor necrosis factor alpha. Brain Res 2006;1120:64-73.
124. Tong L, Balazs R, Soiampornkul R, et al. Interleukin-1beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging 2007 [Epub ahead of print].
125. Barrientos RM, Sprunger DB, Campeau S, et al. BDNF mRNA expression in rat hippocampus following contextual learning is blocked by intrahippocampal IL-1beta administration. J Neuroimmunol 2004;155:119-26.
126. Hori T, Katafuchi T, Take S, et al. Neuroimmunomodulatory actions of hypothalamic interferon-alpha. Neuroimmunomodulation 1998;5:172-7.
127. Saphier D. Neuroendocrine effects of interferon-alpha in the rat. Adv Exp Med Biol 1995;373:209-18.
128. Raber J, Koob GF, Bloom FE. Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala: comparison with the hypothalamic response. Neurochem Int 1997;30:455-63.
129. Schaefer M, Schwaiger M, Pich M, et al. Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 2003;36:S203-6.
130. Yokoyama M, Suzuki E, Sato T, et al. Effects of intraperitoneal administration of IFN-alpha for one, four, and fourteen days on amino acid levels in various rat brain regions. J Interferon Cytokine Res 2005;25:187-91.
131. Morikawa O, Sakai N, Obara H, et al. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998;349:317-24.
132. Kitagami T, Yamada K, Miura H, et al. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res 2003;978:104-14.
133. Shuto H, Kataoka Y, Horikawa T, et al. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997;747:348-51.
134. Asnis GM, De la Garza R II, Kohn SR, et al. IFN-induced depression: a role for NSAIDs. Psychopharmacol Bull 2003;37:29-50.
135. De La Garza R, Asnis GM, Pedrosa E, et al. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog Neuropsychopharmacol Biol Psychiatry 2005;9:781-92.
136. Yang W, Wang Q, Kanes SJ, et al. Altered RNA editing of serotonin 5-HT2C receptor induced by interferon: implications for depression associated with cytokine therapy. Brain Res Mol Brain Res 2004;124:70-8.
137. 1 receptor. J Neurosci 2006;26:10387-96.
138. Gurevich I, Englander MT, Adlersberg M, et al. Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission. J Neurosci 2002;22:10529-32.
139. Cassidy EM, Manning D, Byrne S, et al. Acute effects of low-dose interferon-alpha on serum cortisol and plasma interleukin-6. J Psychopharmacol 2002;16:230-4.
140. Shimizu H, Ohtani K, Sato N, et al. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration. Endocr J 1995;42:551-6.
141. Gisslinger H, Svoboda T, Clodi M, et al. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 1993;57:489-95.
142. Anisman H, Hayley S, Merali Z. Cytokines and stress: sensitization and cross-sensitization. Brain Behav Immun 2003;17:86-93.
143. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999-1010.
144. Kendler KS, Thornton LM, Gardner CO. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry 2001;158:582-6.
145. Wedzony K, Mackowiak M, Fijal K, et al. Evidence that conditioned stress enhances outflow of dopamine in rat prefrontal cortex: a search for the influence of diazepam and 5-HT1A agonists. Synapse 1996;24:240-7.
146. Harvey BH, Naciti C, Brand L, et al. Endocrine, cognitive and hippocampal/cortical 5HT 1A/2A receptor changes evoked by a time-dependent sensitisation (TDS) stress model in rats. Brain Res 2003;983:97-107.
147. Maier SF, Watkins LR. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci Biobehav Rev 2005;29:829-41.
148. Pacchioni AM, Gioino G, Assis A, et al. A single exposure to restraint stress induces behavioral and neurochemical sensitization to stimulating effects of amphetamine: involvement of NMDA receptors. Ann N Y Acad Sci 2002;965:233-46.
149. Flores C, Stewart J. Basic fibroblast growth factor as a mediator of the effects of glutamate in the development of long-lasting sensitization to stimulant drugs: studies in the rat. Psychopharmacology (Berl) 2000;151:152-65.
150. Hayley S, Wall P, Anisman H. Sensitization to the neuroendocrine, central monoamine and behavioral effects of murine tumor necrosis factor-α: peripheral and central mechanisms. Eur J Neurosci 2002; 15:1061-76.
151. Tilders FJH, Schmidt ED, De Goeij DCE. Phenotypic plasticity of CRF neurons during stress. Ann N Y Acad Sci 1993;697:39-52.
152. Schmidt ED, Janszen AWJW, Wouterlood FG, et al. Interleukin-1 induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH) neurons and hyperresponsiveness of the hypothalamic-pituitary-adrenal axis. J Neurosci 1995;15:7417-26.
153. Johnson JD, O'Connor KA, Watkins LR, et al. The role of IL-1beta in stress-induced sensitization of proinflammatory cytokine and corticosterone responses. Neuroscience 2004;127:569-77.
154. Bonaccorso S, Maier SF, Meltzer HY, et al. Behavioral changes in rats after acute, chronic and repeated administration of interleukin-1beta: relevance for affective disorders. J Affect Disord 2003;77:143-8.
155. Maes M, Ombelet W, De Jongh R, et al. The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system. J Affect Disord 2001;63:85-92.
156. Meaney MJ, Szyf M, Seckl JR. Epigenetic mechanisms of perinatal programming of hypothalamic-pituitary-adrenal function and health. Trends Mol Med 2007l;13:269-77.
157. Shanks N, Windle RJ, Perks PA, et al. Early-life exposure to endotoxin alters hypothalamic-pituitary-adrenal function and predisposition to inflammation. Proc Natl Acad Sci U S A 2000;97:5645-50.
158. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 2001;933:222-34.
159. Kusnecov AW, Liang R, Shurin G. T-lymphocyte activation increases hypothalamic and amygdaloid expression of CRH mRNA and emotional reactivity to novelty. J Neurosci 1999;19:4533-43.
160. Bret-Dibat JL, Bluthe RM, Kent S, et al. Lipopolysaccharide and interleukin-1 depress food-motivated behavior in mice by a vagal-mediated mechanism. Brain Behav Immun 1995;9:242-6.
161. Bluthe RM, Dantzer R, Kelley KW. Central mediation of the effects of interleukin-1 on social explorationand body weight in mice. Psychoneuroendocrinology 1997;22:1-11.
162. Yirmiya R, Pollak Y, Barak O, et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001;24:531-44.
163. Castanon N, Konsman JP, Medina C, et al. Chronic treatment with the antidepressant tianeptine attenuates lipopolysaccharide-induced Fos expression in the rat paraventricular nucleus and HPA axis activation. Psychoneuroendocrinology 2003;28:19-34.
164. De La Garza R, Fabrizio KR, Radoi GE, et al. Diclofenac sodium attenuates lipopolysaccharide-induced alterations to reward behavior and corticosterone release. Behav Brain Res 2004;149:77-85.
165. Bugajski J, Gadek-Michalska A, Bugajski AJ. Effect of cyclooxygenase inhibitors on the CRH-induced pituitary-adrenocortical activity during crowding stress. J Physiol Pharmacol 2003;54:99-108.
166. Hollis JH, Evans AK, Bruce KP, et al. Lipopolysaccharide has indomethacin-sensitive actions on Fos expression in topographically organized subpopulations of serotonergic neurons. Brain Behav Immun 2006;20:569-77.
167. Anisman H, Kokkinidis L, Borowski T, et al. Differential effects of IL-1, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res 1998;779:177-87.
168. Anisman H, Kokkinidis L, Merali Z. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun 2002;16:544-56.
169. Merali Z, Brennan K, Brau P, et al. Dissociating anorexia and anhedonia elicited by interleukin-1α: antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake. Psychopharmacology (Berl) 2002;165:413-8.
170. Larson SJ, Romanoff RL, Dunn AJ, et al. Effects of interleukin-1beta on food-maintained behavior in the mouse. Brain Behav Immun 2002;16:398-410.
171. Borowski T, Kokkinidis L, Merali Z, et al. Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia. Neuroreport 1998;9:3797-802.
172. van der Meer MJ, Sweep CG, Pesman GJ, et al. Chronic stimulation of the hypothalamus-pituitary-adrenal axis in rats by interleukin 1beta: central and peripheral mechanisms. Cytokine 1996;8:910-9.
173. Parsadaniantz SM, Lebeau A, Duval P, et al. Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male rat. J Neuroendocrinol 2000;12:766-73.
174. Niimi M, Sato M, Wada Y, et al. Effect of continuous intravenous injection of interleukin-6 and pretreatment with cyclooxygenase inhibitor on brain c-fos expression in the rat. Neuroendocrinology 1997;66:47-53.
175. Fahey B, Hickey B, Kelleher D, et al. The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats. Behav Brain Res 2007;182:80-7.
176. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001;15:199-226.
177. Simon NM, McNamara K, Chow CW, et al. A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 2008;18:230-3.
178. Basterzi AD, Aydemir C, Kisa C, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005;20:473-6.
179. Sluzewska A, Rybakowski JK, Laciak M, et al. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci 1995;762:474-6.
180. Tuglu C, Kara SH, Caliyurt O, et al. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003;170:429-33.
181. Anisman H, Ravindran AV, Griffiths J, et al. Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol Psychiatry 1999b;46:1649-55.
182. Eller T, Vasar V, Shlik J, et al. Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:445-50.
183. Irwin M. Immune correlates of depression. Adv Exp Med Biol 1999; 461:1-24.
184. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999;33:407-18.
185. Cover H, Irwin M. Immunity and depression: insomnia, retardation and reduction of natural killer cell activity. J Behav Med 1994;17:217-23.
186. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-52.
187. Wright CE, Strike PC, Brydon L, et al. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun 2005;19:345-50.
188. Bonaccorso S, Puzella A, Marino V, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22: 86-90.
189. Capuron L, Ravaud A, Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 2000;18:2143-51.
190. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643-52.
191. Capuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003;160:1342-5.
192. Maes M, Bonaccorso S. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C. ACTA Psychiat Scand 2004;109:126-131.
193. Maes M, Capuron L, Ravaud A, et al. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacology 2001;24:130-40.
194. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of the depression and neurotoxicity induced by high dose interferon alpha. N Engl J Med 2001;344:961-6.
195. Scalori A, Pozzi M, Bellia V, et al. Interferon-induced depression: prevalence and management. Dig Liver Dis 2005;37:102-7.
196. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004;29:11-7.
197. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002;5:375-88.
198. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995;13:561-6.
199. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004;82:175-90.
200. Quarantini LC, Bressan RA, Galvão A, et al. Incidence of psychiatric side effects during pegylated interferon-alpha retreatment in nonresponder hepatitis C virus-infected patients. Liver Int 2007;27: 1098-102.
201. Beratis S, Katrivanou A, Georgiou S, et al. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment. J Psychosom Res 2005;58:15-8.
202. Capuron L, Ravaud A, Miller AH, et al. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004;18:205-13.
203. Young SN, Leyton M. The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels. Pharmacol Biochem Behav 2002;71:857-65.
204. Capuron L, Ravaud A, Neveu PJ, et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7:468-73.
205. Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72-week prospective study. AIDS 2005;19 Suppl 3:S174-8.
206. Wichers MC, Kenis G, Leue C, et al. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006;60:77-9.
207. Robaeys G, De Bie J, Wichers MC, et al. Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks. World J Gastroenterol 2007;13:5736-40.
208. Kraus MR, Schafer A, Al-Taie O, et al. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005;12:96-100.
209. Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-9.
210. Maddock C, Baita A, Orru MG, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004;18:41-6.
211. Schramm TM, Lawford BR, Macdonald GA, et al. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000;173:359-61.
212. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007;25:1163-74.
213. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42:793-8.
214. Morasco BJ, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007;103:83-90.
215. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31.
216. Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005;19:105-23.
217. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-4.
218. de Jong JC, van den Berg PB, Tobi H, et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003;55:591-5.
219. Chiou SH, Chen SJ, Peng CH, et al. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys Res Commun 2006;343:391-400.
220. Reynolds JL, Ignatowski TA, Sud R, et al. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience 2005;133:519-31.
221. Reynolds JL, Ignatowski TA, Sud R, et al. Brain derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. J Pharmacol Exp Ther 2004;310:1216-25.
222. Myint AM, O'Mahony S, Kubera M, et al. Role of paroxetine in interferon-alpha-induced immune and behavioural changes in male Wistar rats. J Psychopharmacol 2007;21:843-50.
223. Brustolim D, Ribeiro-dos-Santos R, Kast RE, et al. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol 2006;6:903-7.
224. Obuchowicz E, Kowalski J, Labuzek K, et al. Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures. Int J Neuropsychopharmacol 2006;9:27-35.
225. Griswold DE, Webb EF, Badger AM, et al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 1998;287:705-11.
226. Zhu J, Mix E, Winblad B. The antidepressant and anti-inflammatory effects of rolipram in the central nervous system. CNS Drug Rev 2001;7:387-98.
227. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005;66:1050-7.
228. Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-12.
229. Lieb K, Engelbrecht MA, Gut O, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry 2006;21:204-10.
230. Charlton BG. The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic. Med Hypotheses 2000;54:126-30.
231. Wichers MC, Koek GH, Robaeys G, et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10:538-44.
232. Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007;21:9-19.
233. Kassed CA, Herkenham M. NF-kappaB p50-deficient mice show reduced anxiety-like behaviors in tests of exploratory drive and anxiety. Behav Brain Res 2004;154:577-84.
234. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004;27:589-94.
235. Barger SW, Moerman AM, Mao X. Molecular mechanisms of cytokine-induced neuroprotection: NFkappaB and neuroplasticity. Curr Pharm Des 2005;11:985-98.
236. Miller AH, Raison CL. Cytokines, p38 MAP kinase and the pathophysiology of depression. Neuropsychopharmacology 2006;31: 2089-90.
237. Kaneko N, Kudo K, Mabuchi T, et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 2006;31:2619-26.
238. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003;302:1760-5.
239. Vallieres L, Campbell IL, Gage FH, et al. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci 2002;22:486-92.